Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• Diagnosis of ocular hypertension or open-angle glaucoma in at least 1 eye requiring treatment with an anti-glaucoma/ocular hypertensive medication

• Best corrected visual acuity score of 20/100 or better in both eyes

• Females on birth control pills must be on same type of pill and dose for at least 3 month

Exclusion Criteria:

• Use of Lumigan® 0.01%/Lumigan® RC, Lumigan®, Travatan® or Travatan Z® within 6 months

• History of or active ocular infection/inflammation (eg, uveitis)

• Punctal plug use

• Required use of ocular medications during the study other than study medication (intermittent use of certain types artificial tears acceptable)

• Intraocular surgery or glaucoma laser surgery in study eye(s) within 3 months

• History of corneal refractive laser surgery (eg, LASIK, LASEK) in study eye(s)

• Planned contact lens wear during study